NVSNovartis PharmaceuticalsFinished
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due May 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 62 (final count)
- Started
- May 16, 2023
- Main results expected
- May 17, 2024
- Fully finished
- Apr 22, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Main part: Confirmed Overall Response Rate (ORR) per Blinded Independent Central Review (BICR)
Measured over: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, approx. 1 year
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-05-17, no fading
Raw record changes
- none yet
Trial ID NCT05670106 · record last updated 2026-09-15 · checked 2026-11-09 15:47 UTC